Intra Cellular Therapies reported $848.34M in Current Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 542.22M 75.6M
Aptinyx Inc APTX:US $ 106.53M 8.22M
Biocryst Pharmaceuticals BCRX:US $ 511.71M 54.42M
Biogen BIIB:US $ 7915.9M 59.4M
Bristol Myers Squibb BMY:US $ 30121M 3141M
Cytokinetics CYTK:US $ 623.53M 87.85M
Esperion Therapeutics ESPR:US $ 290.82M 38.15M
Gilead Sciences GILD:US $ 12629M 2143M
Halozyme Therapeutics HALO:US $ 988.69M 62.4M
Intra Cellular Therapies ITCI:US $ 848.34M 381.06M
JAZZ PHA JAZZ:US $ 2500.86M 110.48M
Johnson & Johnson JNJ:US $ 60424M 555M
Marinus Pharmaceuticals MRNS:US $ 135.07M 3.39M
Minerva Neurosciences NERV:US $ 55.7M 6.5M
Nektar Therapeutics NKTR:US $ 733.46M 62.13M
Neurocrine Biosciences NBIX:US $ 1018.2M 45.4M
Novartis NVS:US $ 37236M 8482M
Prothena PRTA:US 555.62M 29.19M
Supernus Pharmaceuticals SUPN:US $ 568.52M 33.07M
United Therapeutics UTHR:US $ 2586.6M 263M
Vanda Pharmaceuticals VNDA:US $ 492.27M 13.97M